Cost-effectiveness analysis of a randomized clinical trial of early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration
- 11 February 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 106 (5), 555-562
- https://doi.org/10.1002/bjs.11082
Abstract
Background Treatment of superficial venous reflux in addition to compression therapy accelerates venous leg ulcer healing and reduces ulcer recurrence. The aim of this study was to evaluate the costs and cost‐effectiveness of early versus delayed endovenous treatment of patients with venous leg ulcers. Methods This was a within‐trial cost‐utility analysis with a 1‐year time horizon using data from the EVRA (Early Venous Reflux Ablation) trial. The study compared early versus deferred endovenous ablation for superficial venous truncal reflux in patients with a venous leg ulcer. The outcome measure was the cost per quality‐adjusted life‐year (QALY) over 1 year. Sensitivity analyses were conducted with alternative methods of handling missing data, alternative preference weights for health‐related quality of life, and per protocol. Results After early intervention, the mean(s.e.m.) cost was higher (difference in cost per patient £163(318) (€184(358))) and early intervention was associated with more QALYs at 1 year (mean(s.e.m.) difference 0·041(0·017)). The incremental cost‐effectiveness ratio (ICER) was £3976 (€4482) per QALY. There was an 89 per cent probability that early venous intervention is cost‐effective at a threshold of £20 000 (€22 546)/QALY. Sensitivity analyses produced similar results, confirming that early treatment of superficial reflux is highly likely to be cost‐effective. Conclusion Early treatment of superficial reflux is highly likely to be cost‐effective in patients with venous leg ulcers over 1 year. Registration number: ISRCTN02335796 (http://www.isrctn.com).Keywords
Funding Information
- Health Technology Assessment Programme (11/129/197)
- Health Technology Assessment Programme (11/129/197)
This publication has 17 references indexed in Scilit:
- A Randomized Trial of Early Endovenous Ablation in Venous UlcerationNew England Journal of Medicine, 2018
- Valuing health-related quality of life: An EQ-5D-5L value set for EnglandHealth Economics, 2017
- Management of Patients With Venous Leg Ulcers: Challenges and Current Best PracticeJournal of Wound Care, 2016
- Health economic burden that wounds impose on the National Health Service in the UKBMJ Open, 2015
- Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trialHealth Technology Assessment, 2015
- A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled TrialsPharmacoEconomics, 2014
- CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENTInternational Journal of Technology Assessment in Health Care, 2013
- Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value SetsValue in Health, 2012
- Quality of life of people with venous leg ulcers: A comparison of the discriminative and responsive characteristics of two generic and a disease specific instrumentsQuality of Life Research, 2005
- Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utilityHealth Economics, 2004